- Poster presentation
- Open Access
Feasibility of dc vaccine combined with low dose endoxan and high dose il-2 treatment associated with taurolidine for advanced, multi-resistant melanoma patients.
© Moviglia and Kleef 2015
Published: 4 November 2015
2014 Dillman and coworkers reported 40% 5-year survival of advanced malignant melanoma (MM) patients treated with a combination of Tumor Vaccine in combination with High dose IL-2 versus 13% of similar patients treated only with High Dose of IL-2 (HD IL-2). In order to improve the efficacy of this approach and minimize the adverse effects of HD IL-2 therapy we have developed a protocol using a Dendritic Cell Vaccine challenged with autologous MM stem cells in combination with HD IL-2 and to Taurolidine (to diminish the vasculary leak syndrome).
5 advanced and rapidly progressive MM patients, resistant to any other standard therapy were treated. 1/5 with large brain metastasis was withdrawn from the treatment after the first cycle of treatment for rapid progression of his disease. 4/5 patients received three cycles. In brief, previous to vaccination with a patient specific autologous dendritic cell vaccine patients underwent low dose endoxan 300m/m2, and were subsequently treated for 5 days with high-dose IL-2 in combination with Taurolidine as described by O'Brian et.al. 2006.
Major side effects were high temperature 4/4 and hypereosinophilia associated with itching (2/5). No other signs like severe edema, renal failure or any other life threatening condition was observed. 4/5 patients did not show any progression of their condition during the 2-3 months of observation.
DC-vaccine associated to HD IL-2 + Taurolidine vaccine seems to be a feasible and low toxic treatment. Longer observation time as well as increment of the number of patients treated is necessary to confirm these preliminary findings.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.